- Home
- AUST vs BOLD Comparison
AUST vs BOLD Comparison
Compare AUST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AUST | BOLD |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 28.4M |
| IPO Year | 2022 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AUST | BOLD |
|---|---|---|
| Price | $2.20 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 2.9M | 125.9K |
| Earning Date | 02-26-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $1.00 |
| 52 Week High | $3.92 | $2.54 |
Technical Indicators
Market Signals| Indicator | AUST | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 67.30 | 46.13 |
| Support Level | $1.71 | $1.19 |
| Resistance Level | $3.92 | $1.31 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 26.60 | 12.50 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.